180 related articles for article (PubMed ID: 37476993)
1. Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias.
Meda F; Simrén J; Borroni B; Cantoni V; Archetti S; Biasiotto G; Andreasson U; Blennow K; Kvartsberg H; Zetterberg H
Clin Chem Lab Med; 2023 Nov; 61(12):2195-2204. PubMed ID: 37476993
[TBL] [Abstract][Full Text] [Related]
2. A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy.
Sassi C; Capozzo R; Gibbs R; Crews C; Zecca C; Arcuti S; Copetti M; Barulli MR; Brescia V; Singleton AB; Logroscino G
J Alzheimers Dis; 2016 May; 53(2):475-85. PubMed ID: 27258413
[TBL] [Abstract][Full Text] [Related]
3. Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.
Alquézar C; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
J Psychiatry Neurosci; 2016 Jun; 41(4):225-39. PubMed ID: 26624524
[TBL] [Abstract][Full Text] [Related]
4. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations.
Huang M; Modeste E; Dammer E; Merino P; Taylor G; Duong DM; Deng Q; Holler CJ; Gearing M; Dickson D; Seyfried NT; Kukar T
Acta Neuropathol Commun; 2020 Oct; 8(1):163. PubMed ID: 33028409
[TBL] [Abstract][Full Text] [Related]
5. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.
Holler CJ; Taylor G; McEachin ZT; Deng Q; Watkins WJ; Hudson K; Easley CA; Hu WT; Hales CM; Rossoll W; Bassell GJ; Kukar T
Mol Neurodegener; 2016 Jun; 11(1):46. PubMed ID: 27341800
[TBL] [Abstract][Full Text] [Related]
6. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.
Ward ME; Chen R; Huang HY; Ludwig C; Telpoukhovskaia M; Taubes A; Boudin H; Minami SS; Reichert M; Albrecht P; Gelfand JM; Cruz-Herranz A; Cordano C; Alavi MV; Leslie S; Seeley WW; Miller BL; Bigio E; Mesulam MM; Bogyo MS; Mackenzie IR; Staropoli JF; Cotman SL; Huang EJ; Gan L; Green AJ
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404863
[TBL] [Abstract][Full Text] [Related]
7. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.
Finch N; Baker M; Crook R; Swanson K; Kuntz K; Surtees R; Bisceglio G; Rovelet-Lecrux A; Boeve B; Petersen RC; Dickson DW; Younkin SG; Deramecourt V; Crook J; Graff-Radford NR; Rademakers R
Brain; 2009 Mar; 132(Pt 3):583-91. PubMed ID: 19158106
[TBL] [Abstract][Full Text] [Related]
8. Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by
Holler CJ; Taylor G; Deng Q; Kukar T
eNeuro; 2017; 4(4):. PubMed ID: 28828399
[TBL] [Abstract][Full Text] [Related]
9. Peripheral GRN mRNA and Serum Progranulin Levels as a Potential Indicator for Both the Presence of Splice Site Mutations and Individuals at Risk for Frontotemporal Dementia.
Guven G; Bilgic B; Tufekcioglu Z; Erginel Unaltuna N; Hanagasi H; Gurvit H; Singleton A; Hardy J; Emre M; Gulec C; Bras J; Guerreiro R; Lohmann E
J Alzheimers Dis; 2019; 67(1):159-167. PubMed ID: 30475763
[TBL] [Abstract][Full Text] [Related]
10. Progranulin peripheral levels as a screening tool for the identification of subjects with progranulin mutations in a Portuguese cohort.
Almeida MR; Baldeiras I; Ribeiro MH; Santiago B; Machado C; Massano J; Guimarães J; Resende Oliveira C; Santana I
Neurodegener Dis; 2014; 13(4):214-23. PubMed ID: 24022032
[TBL] [Abstract][Full Text] [Related]
11. Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations.
Arrant AE; Roth JR; Boyle NR; Kashyap SN; Hoffmann MQ; Murchison CF; Ramos EM; Nana AL; Spina S; Grinberg LT; Miller BL; Seeley WW; Roberson ED
Acta Neuropathol Commun; 2019 Dec; 7(1):218. PubMed ID: 31870439
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.
Kashyap SN; Boyle NR; Roberson ED
Neurotherapeutics; 2023 Jan; 20(1):140-153. PubMed ID: 36781744
[TBL] [Abstract][Full Text] [Related]
13. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.
Kurnellas M; Mitra A; Schwabe T; Paul R; Arrant AE; Roberson ED; Ward M; Yeh F; Long H; Rosenthal A
J Transl Med; 2023 Jun; 21(1):387. PubMed ID: 37322482
[TBL] [Abstract][Full Text] [Related]
14. Progranulin as a therapeutic target for dementia.
Galimberti D; Fenoglio C; Scarpini E
Expert Opin Ther Targets; 2018 Jul; 22(7):579-585. PubMed ID: 29889573
[TBL] [Abstract][Full Text] [Related]
15. Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.
Arrant AE; Nicholson AM; Zhou X; Rademakers R; Roberson ED
Mol Neurodegener; 2018 Jun; 13(1):32. PubMed ID: 29929528
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.
Wilke C; Gillardon F; Deuschle C; Hobert MA; Jansen IE; Metzger FG; Heutink P; Gasser T; Maetzler W; Blauwendraat C; Synofzik M
Neurodegener Dis; 2017; 17(2-3):83-88. PubMed ID: 27760429
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Progranulin Gene Mutations in Portuguese Patients with Frontotemporal Dementia.
Almeida MR; Tábuas-Pereira M; Baldeiras I; Lima M; Durães J; Massano J; Pinto M; Cruto C; Santana I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203682
[TBL] [Abstract][Full Text] [Related]
18. Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.
Arrant AE; Onyilo VC; Unger DE; Roberson ED
J Neurosci; 2018 Feb; 38(9):2341-2358. PubMed ID: 29378861
[TBL] [Abstract][Full Text] [Related]
19. Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression.
Khrouf W; Saracino D; Rucheton B; Houot M; Clot F; Rinaldi D; Vitor J; Huynh M; Heng E; Schlemmer D; Pasquier F; Deramecourt V; Auriacombe S; Azuar C; Levy R; Bombois S; Boutoleau-Brétonnière C; Pariente J; Didic M; Wallon D; Fluchère F; Auvin S; Younes IB; ; ; Nadjar Y; Brice A; Dubois B; Bonnefont-Rousselot D; Le Ber I; Lamari F
Neurobiol Dis; 2023 Jun; 181():106108. PubMed ID: 37003407
[TBL] [Abstract][Full Text] [Related]
20. rs5848 polymorphism and serum progranulin level.
Hsiung GY; Fok A; Feldman HH; Rademakers R; Mackenzie IR
J Neurol Sci; 2011 Jan; 300(1-2):28-32. PubMed ID: 21047645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
